PROGNOSTIC FACTORS AFFECTING THE OUTCOME OF PATIENTS WITH ACUTE ISCHEMIC STROKE TREATED WITH INTRAVENOUS THROMBOLYSIS

Thesis

Submitted for partial fulfillment of master's degree in neuropsychiatry

Presented by

Dina Ahmed Ali Soliman

M.B., B.Ch

Supervised by

Prof. Mahmoud Hemeda El- Rakawy

Professor of Neurology

Faculty of Medicine, Ain Shams University

Prof. Yousry Abo El Naga Abdel El Hamid

Professor of Neurology

Faculty of Medicine, Ain Shams University

Dr. Mohamed Amir Tork

Assistant Professor of Neurology

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

2018

العوامل المؤثرة على تحسن مرضى السكتة الدماغية الحادة بعد تلقي عقار مذيب الجلطات عن طريق الحقن الوريدي

رسالة

توطئة للحصول علي درجة الماجستير في طب المخ والأعصاب و الطب النفسي

مقدمة من

دينا أحمد علي سليمان الطيبة /

بكالوريوس الطب والجراحة العامة كلية الطب- جامعة عين شمس

تحت إشراف

أ.د / محمود حميدة الرقاوي

أستاذ طب المخ و الأعصاب

كلية الطب-جامعة عين شمس

أ.د / يسري ابو النجا عبد الحميد

أستاذ طب المخ و الأعصاب

كلية الطب- جامعة عين شمس

د / محمد أمير ترك

استاذ مساعد طب المخ و الأعصاب

كلية الطب- جامعة عين شمس

٢٠١٨

سورة البقرة الآية: ٣٢

First and foremost thanks to ALLAH, the Most Merciful.

I wish to express my sincere and deepest gratitude to ***Prof. Mahmoud Hemeda El Rakawy*** *Professor of Neurology, Faculty of Medicine, Ain Shams University, for meticulous revision of this work, constructive criticism, faithful guidance and tremendous support that enable me to accomplish this work.*

I am profoundly grateful to ***Prof. Yousry Abo El Naga Abdelhamid,*** *Professor of Neurology, Faculty of medicine, Ain Shams University for his continuous encouragement, valuable support and generous recommendations.*

My sincere thanks and deep appreciation goes to ***Dr. Mohamed Amir Tork,*** *assistant professor of Neurology, Faculty of Medicine, Ain Shams University for his sincere advice and kind cooperation in all steps of this work.*

I also wish to thank all my professors, colleagues and all staff members of neuropsychiatry department, Faculty of Medicine, Ain Shams University, and my family for their encouragement and cooperation and for helping me through my residency.

Contents

Subjects	Page

- **Introduction** .....
- **Aim of the Work**.....
- **Review of literature:** .....

Chapter (1): Epidemiology and Risk factors for acute ischemic cerebrovascular stroke. .....

Chapter (2): Management of acute ischemic stroke.....

Chapter (3): Intravenous thrombolysis.....

Chapter (4): Complications and Barriers decreasing the use of intravenous thrombolysis in acute ischemic stroke management. .....

- **Patients And Methods**.....
- **Results**.....
- **Discussion**.....
- **Strengths &Limitations** .....
- **Conclusion** .....
- **Recommendations** .....
- **Summary** .....
- **References** .....
- **Arabic Summary** ..... -

List of Abbreviations

ABC	:	Airway, Breathing, Circulation.
ACS	:	Acute Coronary Syndrome.
ADP	:	Adenosine diphosphate
AF	:	Atrial Fibrillation.
AHA	:	American Heart Association.
ASA	:	American Stroke Association.
aPTT	:	activated Partial Thromboplastin Time.
ASRHs	:	Acute Stroke Ready Hospitals.
ASUSH	:	Ain Shams University Specialized Hospital.
ATLANTIS	:	The Alteplase Thrombolysis for Acute Non Interventional Therapy in Ischemic Stroke.
AVM	:	Arteriovenous Malformation.
BBB	:	Blood Brain Barrier.
BP	:	Blood Pressure.
CE	:	Cardioembolism.
CAA	:	Cerebral Amyloid Angiopathy.
CADASIL	:	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.
CAPRIE	:	Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events.
CARASIL	:	Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
CASES	:	Canadian Alteplase for Stroke Effectiveness Study
CED	:	Cerebral Brain Edema
CHD	:	Chronic Heart Disease.
CRP	:	C-reactive protein.
CSC	:	Comprehensive Stroke Center.
CT	:	Computed Tomography.
CTA	:	Computed Tomography Angiography.
DALYs	:	Disability Adjusted Life Years Analysis.
DBP	:	Diastolic Blood Pressure.
DM	:	Diabetes Milletus
DVT	:	Deep Venous Thrombosis.
DWI	:	Diffusion Weighted Imaging .
ECASS 1	:	First European Cooperative Acute Stroke Study.
ECT	:	Ecarin Clotting Time.
ED	:	Emergency Department.
EF%	:	Ejection fraction.
EICs	:	Early Ischemic Changes.
EMS	:	Emergency Medical System.

END	:	End of life stroke care.
ESC	:	European Stroke Conference.
ESPRIT	:	The European \Australian Stroke Prevention in Reversible Ischemia Trial.
ESPS-2	:	Second European Stroke Prevention Study.
FDA	:	Food and Drug Administration.
FFP	:	Fresh Frozen Plasma.
GSC	:	Glasgow Coma Scale.
HbA1C	:	Glycated hemoglobin.
HBP	:	High Blood Pressure.
HT	:	Hemorrhagic Transformation.
ICA		Internal carotid artery
ICD10	:	The 10th revision of the International Statistical Classification of Diseases and Related Health Problems
ICP		Intracranial Pressure.
IMS-111	:	International Management of Acute Stroke Study-111 .
INR	:	International Normalized Ratio.
IS	:	Ischemic Stroke.
IHD	:	Ischemic heart disease
IST	:	International Stroke Trial.
IV	:	Intravenous.
IVT	:	Intravenous thrombolytic therapy.
J-ACT	:	The Japan-Alteplase Clinical Trial.
LA	:	Left Atrium.
LAA	:	Large Artery Astherosclerosis.
LAD	:	Left Atrial Diameter.
LMWH	:	Low Molecular Weight Heparin.
LV	:	Left Ventricle.
MCA	:	Middle Cerebral Artery.
MELAS	:	Mitochondrial Encephalopathy, Lactic acidosis and Stroke like episode.
MI	:	Myocardial Infarction.
MRA	:	Magnetic Resonance Angiography.
mRS	:	modified Rankin Scale.
MRI	:	Magnetic Resonance Imaging.
NIHSS	:	National Institutes of Health Stroke Scale.
NINDS	:	National Institute Of Neurological Disorders And Stroke.
NMDA	:	N-Methyl-D-Aspartic acid.
NOMASS	:	Northern Manhattan Stroke Study.

Non STEMI	**:**	Non ST segment Elevation Myocardial Infarction.
OSAS	**:**	Obstructive Sleep Apnea Syndrome.
PCC	**:**	Prothrombin Complex Concentrate
PCS	**:**	Posterior circulation stroke
PH		Parenchymal Hemorrhage.
PSC	**:**	Primary Stroke Center.
PT	**:**	Prothrombin Time.
PWI	**:**	Perfusion Weighted Imaging.
RHD	**:**	Rhematic heart disease
SAH	**:**	Subarachnoid Hemorrhage.
SBP	**:**	Systolic Blood Pressure.
sICH	**:**	symptomatic Intracranial Hemorrhage.
SITS-MOST	**:**	The Safe Implementation of Thrombolysis in Stroke Monitering Study.
(SITS-ISTR)	**:**	Safe Implementation of Thrombolysis in Stroke– International Stroke Thrombolysis Registry.
STEMI	**:**	ST segment Elevation Myocardial Infarction.
TASS	**:**	Ticlopedine Aspirin Stroke Study.
TCD	**:**	Trans cranial Doppler.
TIA	**:**	Transient Ischemic Attack.
TOAST	**:**	Trial of Org 10172 in Acute Stroke Treatment.
TPA	**:**	Tissue Plasminogen Activator.
r-tPA	**:**	recombinant Tissue Plasminogen Activator.
TT	**:**	Thrombin Time.
TTT-AIS	**:**	Taiwan Thrombolytic Therapy for Acute Ischemic Stroke.
US	**:**	United States.
WHO	**:**	World Health Organization.

List of Tables

Tab. No.	Subject	Page
Table (1)	Distribution of the patients in the study regarding sociodemographic data.	118
Table (2)	Distribution of the patients in the study regarding past medical history.	121
Table (3)	Distribution of the studied patients regarding the time between symptoms onset, reaching the hospital where r-tPA is given and the start of r-tPA therapy (onset to door, door to needle and onset to needle time).	123
Table (4)	Distribution of our patients regarding the conscious level examination on admission.	126
Table (5)	Laboratory investigations of the patients in the study.	128
Table (6)	Echocardiography findings of the studied patients.	129
Table (7)	Distribution of the studied patients regarding the results of different diagnostic methods (carotid duplex, CT brain and MRI brain) and the classification of types of acute ischemic stroke (ICD10 and TOAST).	131
Table (8)	Distribution of the studied patients regarding the complications of r-tPA therapy.	135
Table (9)	Distribution of the studied patients regarding the global outcome upon discharge.	136
Table (10)	Distribution of the patients in the study, treated with IVT, regarding their compliance on acute ischemic stroke treatment in the following up after 3 months.	139
Table (11)	Distribution of the patients in the study, treated with IVT, regarding undergoing physiotherapy sessions in the following up after 3 months.	139
	Distribution of the studied patients regarding the	140

Tab. No.	Subject	Page
Table (12)	global outcome after 3 months follow up.	
Table (13)	Mortality rate upon discharge and after 3 months follow up and causes of death of our studied patients.	141
Table (14)	Age as a prognostic factor affecting the global outcome of the studied patients both upon discharge and after 3 months follow up.	142
Table (15)	Gender as a prognostic factor affecting the global outcome of the patients both upon discharge and after 3 months follow up.	144
Table (16)	Smoking as a prognostic factor affecting the global outcome both upon discharge and 3 months later.	145
Table (17)	Diabetes mellitus as a prognostic factor affecting the global outcome upon discharge and 3 months later.	146
Table (18)	Hypertension as a prognostic factor affecting the global outcome of acute stroke patients both upon discharge and after 3 months follow up.	148
Table (19)	Previous stroke (3 months ago or longer) as a prognostic factor on the global outcome of acute stroke patients treated by IVT upon discharge and after 3 months follow up.	149
Table (20)	Past history of ischemic heart diseases (IHD) and its effect on the global outcome both upon discharge and after 3 months follow up.	151
Table (21)	Atrial fibrillation (AF) and its effect on the global outcome of acute stroke patients treated by IVT both upon discharge and after 3 months follow up.	152
Table (22)	Global outcome upon discharge in relation to time (onset to door, door to needle and onset to needle times).	153
Table (23)	Global outcome after 3 months follow up in	155

Tab. No.	Subject	Page
	relation to time (onset to door, door to needle and onset to needle times).	
Table (24)	Global outcome upon discharge and after 3 months follow up in relation to blood pressure measurements on admission.	157
Table (25)	Conscious level on admission and its effect on the global outcome of the studied patients both upon discharge and after 3 months follow up.	158
Table (26)	Stroke severity assessment using NIHSS on admission as a prognostic factor affecting the global outcome of the studied patients upon discharge.	160
Table (27)	Stroke severity assessment using NIHSS on admission as a prognostic factor affecting the global outcome of the studied patients 3 months later.	162
Table (28)	Stroke disability assessment using mRS on admission as a prognostic factor affecting the global outcome both upon discharge and after 3 months follow up.	164
Table (29)	Systemic hemorrhage as a complication of r-tPA and its effect on the global outcome both upon discharge and 3 months later.	165
Table (30)	Allergy during infusion of r-tPA and its effect on the global outcome both upon discharge and 3 months later.	166
Table (31)	Hemorrhagic transformation and its effect on the global outcome of the studied patients both upon discharge and 3 months later.	168
Table (32)	Brain edema and its effect on the global outcome both upon discharge and after 3 months follow up.	170
Table (33)	Global outcome of the patients upon discharge in relation to laboratory investigations on	172

Tab. No.	Subject	Page
	admission.	
Table (34)	Global outcome of the studied patients after 3 months follow up in relation to laboratory investigations on admission.	174
Table (35)	The echocardiography findings as a prognostic factor affecting the global outcome of our patients both upon discharge and 3 months later.	177
Table (36)	The effect of carotid stenosis shown in carotid duplex on the global outcome of the studied patients upon discharge and after 3 months follow up.	179
Table (37)	Site of infarction in MRI and its effect on the global outcome of the studied patients both upon discharge and 3 months later.	181
Table (38)	Arterial occlusion in MRA in relation to the global outcome of the studied patients both upon discharge and after 3 months follow up.	184
Table (39)	TOAST classification of acute stroke as a prognostic factor affecting the outcome upon discharge and 3 months later.	186
Table (40)	Correlation between the global outcome of the studied patients after 3 months and compliance on treatment of acute ischemic stroke.	187
Table (41)	The effect of undergoing regular physiotherapy sessions on the global outcome of the studied patients treated with IVT after 3 months follow up.	188

List of Figures

Fig. No.	Subject	Page
Fig. (1)	Stroke Epidemiology in Thailand**.**	9
Fig. (2)	Estimated 10-year stroke risk in adults 55 years of age according to levels of various risk factors (Framingham Heart Study).	16
Fig. (3)	Observed percentage surviving (Kaplan-Meier estimates) free of recurrent stroke after incident ischemic stroke among 531 residents of Erlangen, Bavaria, Germany, 1994 to 1998, with common ischemic stroke subtypes	21
Fig. (4)	Observed percentage surviving (Kaplan-Meier estimates) after incident ischemic stroke among 531 residents of Erlangen, Bavaria, Germany, 1994 to 1998, with common ischemic stroke subtypes.	21
Fig. (5)	The Most common stroke mimics.	23
Fig. (6)	On the left we first have a diffusion image indicating the area with irreversible changes. In the middle there is a large area with hypo-perfusion. On the right there is the diffusion-perfusion mismatch	35
Fig. (7)	71 years old woman presenting with sudden onset of a right face-arm-leg hemi syndrome and non-fluent aphasia. The non-contrast CT demonstrates a left “insular ribbon sign” and subtle left parietal hypo-density. The cerebral infarct and cerebral brain volume abnormality on perfusion-CT show a similar size to the DWI-MRI abnormality. The corresponding M1 occlusion is clearly identified on both the CTA and MRA.	35

Fig. No.	Subject	Page
Fig. (8)	Thrombolysis related (ICH) intra parenchymal hemorrhage in the right temporal lobe with surrounding edema and mass effect resulting in both subfalcine and transtentorial herniation.	82
Fig. (9)	Intra parenchymal brain stem (A) and left lateral intra-ventricular hemorrhage (B) in a patient presenting with a right anterior cerebral artery acute ischemic stroke receiving (IV r-tPA).	86
Fig. (10)	Distribution of PH and sICH according to prior use of aspirin in both treatment groups.	89
Fig. (11)	The golden hour for evaluating and treating acute ischemic stroke by intravenous thrombolytic therapy.	107
Fig. (12)	The distribution of the patients in the study according to gender.	119
Fig. (13)	Distribution of the patients in the study according to smoking habit.	120
Fig. (14)	The causes of delay outside the hospital to reach the emergency department.	124
Fig. (15)	The causes of delay inside the hospital to start the r-tPA therapy.	125
Fig. (16)	National Institutes of Health Stroke Scale (NIHSS) is a scoring system to assess stroke severity on admission.	126
Fig. (17)	mRS is a scoring system to assess stroke disability on admission.	127

Fig. No.	Subject	Page
Fig. (18)	Distribution of the patients in the study according to site of arterial occlusion in magnetic resonance arteriography.	132
Fig. (19)	The distribution of the patients in the study according to stroke severity assessment by (NIHSS) upon discharge.	133
Fig. (20)	The distribution of the patients in the study according to stroke disability assessment using mRS score upon discharge.	134
Fig. (21)	The stroke severity assessment using NIHSS after 3 months follow up.	137
Fig. (22)	The distribution of the patients in the study according to stroke disability assessment using mRS score after 3 months follow up.	138
Fig. (23)	Onset to door time was associated with worse outcome of patients in the study after 3 months follow up (p=0.054).	155
Fig. (24)	Deteriorated conscious level was associated with worse outcome upon discharge (statistically significant).	159
Fig. (25)	Deteriorated conscious level of the patients was associated with worse outcome after 3 months follow up.	159
Fig. (26)	Range of stroke severity assessment using NIHSS on admission of our patients with better, unchanged and worse outcome upon discharge.	161
Fig. (27)	Range of stroke severity assessment using NIHSS on admission of the studied patients with better,	162